Absorption and bioavailability |
After oral administration is
absorbed predominantly by the small intestine and presents
bioavailability of about 50%. |
26-29 |
Distribution |
Distributed and concentrated mainly in the
kidneys, adrenal glands, pancreas and liver. Lower concentrations of MET
are found in the lungs and muscles. |
|
Biotransformation |
MET does not suffer hepatic metabolism. |
|
Excretion |
Approximately 30-50% of an oral dose of MET is
excreted unchanged in the urine over a period of 24 hours and about 30%
of the dose is excreted unchanged in the faeces. |
|
Adverse effects |
Nausea, vomiting, flatulence, diarrhea and
abdominal pain, asthenia, headache, skin rash, ovulation induction and
lactic acidosis. |
|
Contraindications |
Drug allergy, creatinine clearance above
1.4 mL/min in women and 1.5 mL/min in men, metabolic acidosis, lactic
acidosis, iodinated contrast, hypoxemia, dehydration, sepsis, surgery
and liver disease. |
|